{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
IRadimed Corp. Hits New 52-Week High of $87.88, Up 104%
IRadimed Corp. has achieved a new 52-week high, reflecting its strong performance with a significant increase compared to the S&P 500. The company, valued at USD 914 million, showcases robust financial health, highlighted by a high return on equity and consistent positive results over the past year.
Is IRadimed Corp. overvalued or undervalued?
As of October 31, 2025, IRadimed Corp. is considered overvalued with high valuation metrics despite a strong year-to-date return of 57.70%, shifting its valuation grade from attractive to fair.
IRadimed Corp. Stock Soars 9.5%, Hits Intraday High of $85.00
IRadimed Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has shown notable stock performance, with significant gains over various time frames. The company boasts strong financial metrics, including a high return on equity and positive operating cash flow, indicating solid management efficiency and market position.
IRadimed Corp. Hits New 52-Week High of $85.00, Up 97.91%
IRadimed Corp. has achieved a new 52-week high of USD 85.00, reflecting a strong one-year return of 97.91%. The company, with a market capitalization of USD 914 million, shows effective management through a 21.91% return on equity and robust operational performance, including significant cash flow and net sales.
IRadimed Corp. Experiences Revision in Its Stock Evaluation Amid Strong Market Performance
IRadimed Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation metrics, including a P/E ratio of 39 and a PEG ratio of 3.97. The company has shown strong performance, with a return on capital employed of 56.93% and a return on equity of 21.97%.
Is IRadimed Corp. overvalued or undervalued?
As of October 31, 2025, IRadimed Corp. is considered overvalued with a P/E ratio of 39 and a current price of 76.81, despite strong performance metrics like a 39.65% year-to-date return and high ROCE and ROE, indicating a shift in its valuation from attractive to fair.
Is IRadimed Corp. overvalued or undervalued?
As of October 31, 2025, IRadimed Corp. is fairly valued with a P/E ratio of 39 and strong returns, but it appears overvalued compared to peers, as its P/E is higher than the industry average.
IRadimed Corp. Hits New 52-Week High of $79.14, Up 84.64%
IRadimed Corp. has achieved a new 52-week high, reflecting its strong performance with an impressive one-year return. The company, with a market capitalization of USD 914 million, showcases solid financial metrics, including a favorable P/E ratio and low debt-to-equity ratio, alongside consistent operational strength and significant growth in operating profit.
IRadimed Corp. Experiences Evaluation Revision Amid Strong Market Performance and Dynamics
IRadimed Corp., a small-cap in the Pharmaceuticals & Biotechnology sector, has seen its stock rise slightly to $78.47. Over the past year, it has achieved a 55.36% return, significantly outperforming the S&P 500. The stock has reached a 52-week high of $79.14, reflecting its strong market position.
Is IRadimed Corp. overvalued or undervalued?
As of October 17, 2025, IRadimed Corp. is considered undervalued with a favorable valuation grade, a P/E ratio of 39, and strong stock performance, outperforming the S&P 500 significantly year-to-date and over the past five years.
IRadimed Corp. Experiences Valuation Adjustment Amid Strong Market Performance and Competitive Positioning
IRadimed Corp., a small-cap company in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation metrics, showcasing a P/E ratio of 39 and a strong return on capital employed of 56.93%. The company has outperformed the S&P 500 over the past year, indicating a favorable competitive position.
Is IRadimed Corp. overvalued or undervalued?
As of October 17, 2025, IRadimed Corp. is considered an attractive investment due to its favorable valuation metrics, including a P/E ratio of 39 and a PEG ratio of 3.97, along with a year-to-date return of 33.51%, significantly outperforming the S&P 500's 13.30%.
Is IRadimed Corp. overvalued or undervalued?
As of October 17, 2025, IRadimed Corp. is considered undervalued with an attractive valuation grade, highlighted by a P/E ratio of 39, strong ROCE of 56.93%, and a year-to-date return of 33.51%, outperforming the S&P 500.
IRadimed Corp. Hits New 52-Week High of $77.88, Up 80.87%
IRadimed Corp. has achieved a new 52-week high, reflecting an impressive performance with an 80.87% increase over the past year. The company, with a market capitalization of USD 914 million, showcases strong financial metrics, including a P/E ratio of 39.00 and a return on equity of 21.91%.
IRadimed Corp. Hits New 52-Week High of $75.14, Up 74.99%
IRadimed Corp. has achieved a new 52-week high, reflecting a significant performance increase over the past year. With a market capitalization of USD 914 million, a P/E ratio of 39.00, and a return on equity of 21.91%, the company demonstrates strong financial health in the pharmaceuticals and biotechnology sector.
Is IRadimed Corp. technically bullish or bearish?
As of July 30, 2025, IRadimed Corp. shows a bullish technical trend with strong MACD and moving averages, despite mixed signals from the RSI and OBV, and has significantly outperformed the S&P 500 year-to-date and over the past year.
Is IRadimed Corp. overvalued or undervalued?
As of September 3, 2025, IRadimed Corp. has shifted from a fair to an attractive valuation grade, indicating it is undervalued with a P/E ratio of 39, strong year-to-date returns of 31.59%, and a remarkable 5-year return of 224.55%, outperforming both the S&P 500 and its peers.
Is IRadimed Corp. overvalued or undervalued?
As of June 13, 2025, IRadimed Corp. is considered undervalued with an attractive valuation grade, highlighted by a P/E ratio of 39, strong operational efficiency with a ROCE of 56.93%, and a 1-year return of 38.68%, outperforming the S&P 500.
Is IRadimed Corp. technically bullish or bearish?
As of June 4, 2025, IRadimed Corp. shows a strong bullish trend supported by positive indicators across multiple time frames, including bullish MACD, Bollinger Bands, and moving averages.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
